Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Aspira Womens Health's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.
As of Dec. 2023, Aspira Womens Health has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Aspira Womens Health Sloan Ratio % Historical Data
The historical data trend for Aspira Womens Health's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's Sloan Ratio %
For the Diagnostics & Research subindustry, Aspira Womens Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Sloan Ratio % falls into.
Aspira Womens Health Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Aspira Womens Health's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Aspira Womens Health's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -6.067 (Mar. 2023 ) + -2.317 (Jun. 2023 ) + -4.706 (Sep. 2023 ) + -3.089 (Dec. 2023 ) = $-16.18 Mil.
Aspira Womens Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -5.706 (Mar. 2023 ) + -3.417 (Jun. 2023 ) + -3.321 (Sep. 2023 ) + -3.45 (Dec. 2023 ) = $-15.89 Mil.
Aspira Womens Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.008 (Mar. 2023 ) + -0.004 (Jun. 2023 ) + 0 (Sep. 2023 ) + -0.012 (Dec. 2023 ) = $-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (NAS:AWH) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, Aspira Womens Health has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Aspira Womens Health Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (Aspira Womens Health) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AWH has been successfully added to your 